Cerus Corporation
2550 Stanwell Drive
Concord
California
94520
United States
Tel: 925-288-6000
Website: http://www.cerus.com/
446 articles about Cerus Corporation
-
Cerus Corporation to Release Fourth Quarter and Full Year 2022 Financial Results on February 28, 2023
2/15/2023
Cerus Corporation (Nasdaq: CERS) announced today that its fourth quarter and full year 2022 financial results will be released on Tuesday, February 28, 2023, after the close of the stock market.
-
Cerus Corporation to Participate in Upcoming Investor Conferences - February 10, 2023
2/10/2023
Cerus Corporation announced that the Company will participate in two upcoming investor conferences.
-
Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2022 Product Revenue and Provides Business Update
1/9/2023
Cerus Corporation (Nasdaq: CERS) today announced preliminary product revenue for the fourth quarter and full-year 2022 and provided product revenue guidance for full-year 2023.
-
Cerus Corporation to Participate in Upcoming November 2022 Investor Conferences
11/4/2022
Cerus Corporation announced that Vivek Jayaraman, Cerus’ chief operating officer, is scheduled to participate in two conferences.
-
Cerus Corporation Announces Third Quarter 2022 Financial Results
11/3/2022
Cerus Corporation announced financial results for the third quarter ended September 30, 2022.
-
Cerus Corporation Announces Award of U.S. Department of Defense Funding for Development of Pathogen Reduced, Lyophilized Cryoprecipitate
11/2/2022
Cerus Corporation announced that it has been awarded a $9.1 million contract by the U.S. Department of Defense Industrial Base Analysis and Sustainment program for the development of pathogen reduced, lyophilized cryoprecipitate to treat bleeding due to trauma.
-
Cerus Corporation Announces Health Canada Approval for INTERCEPT Blood System for Platelets with Seven-Day Storage
11/1/2022
Cerus Corporation (Nasdaq:CERS) today announced it has received approval from Health Canada to extend the storage of platelets treated with the INTERCEPT Blood System from five days to seven days from the time of collection, joining other territories where INTERCEPT platelets are approved for seven-day storage.
-
Cerus Corporation to Release Third Quarter 2022 Financial Results on November 3, 2022
10/20/2022
Cerus Corporation (Nasdaq: CERS) announced today that its third quarter 2022 financial results will be released on Thursday, November 3, 2022, after the close of the stock market.
-
Cerus Corporation Announces Workshop and Abstracts at the 2022 AABB Annual Meeting
9/26/2022
Cerus Corporation (Nasdaq:CERS) today announced a selection of abstracts and an industry workshop at the 2022 AABB Annual Meeting, taking place in Orlando, FL from October 1 through October 4.
-
Cerus Corporation Acknowledges Growing Monkeypox Outbreak and Public Health Emergency
8/12/2022
Cerus Corporation (Nasdaq: CERS) acknowledges the U.S. Department of Health and Human Services’ declaration of monkeypox as a national Public Health Emergency.
-
Cerus Corporation Announces Another Record Quarter and Reiterates Full Year 2022 Product Revenue Guidance Range
8/4/2022
Cerus Corporation announced financial results for the second quarter ended June 30, 2022.
-
Cerus Corporation to Release Second Quarter 2022 Financial Results on August 4, 2022
7/21/2022
Cerus Corporation (Nasdaq: CERS) announced today that its second quarter 2022 financial results will be released on Thursday, August 4, 2022, after the close of the stock market.
-
Cerus Corporation Announces Appointment of Hua Shan, MD, PhD to Board of Directors
7/5/2022
Cerus Corporation announced the appointment of Hua Shan, MD, PhD, Professor of Pathology and Medical Director, Transfusion Medicine Service at Stanford Medical Center to its Board of Directors.
-
Cerus Corporation Announces First Quarter 2022 Financial Results and Increases Full Year 2022 Product Revenue Guidance Range
5/5/2022
Cerus Corporation announced financial results for the first quarter ended March 31, 2022.
-
Cerus Corporation Announces New Manufacturing and Supply Agreement With Fresenius Kabi For INTERCEPT Blood System Sets
5/3/2022
Cerus Corporation (Nasdaq: CERS) today announced that it has signed a ten-year agreement with Fresenius Kabi for the production of INTERCEPT Blood System sets.
-
Cerus Corporation Announces Multi-Year Contract for the INTERCEPT Blood System for Platelets with the American Red Cross
4/25/2022
Cerus Corporation (Nasdaq: CERS) today announced that it has signed a five-year contract with the American Red Cross for the INTERCEPT Blood System for Platelets.
-
Cerus Corporation to Release First Quarter 2022 Financial Results on May 5, 2022
4/21/2022
Cerus Corporation (Nasdaq: CERS) announced today that its first quarter 2022 financial results will be released on Thursday, May 5, 2022, after the close of the stock market.
-
Cerus Corporation Announces Record Fourth Quarter and Full-Year 2021 Financial Results
2/22/2022
Cerus Corporation announced financial results for the fourth quarter and full year ended December 31, 2021.
-
Cerus Corporation to Release Fourth Quarter and Full-Year 2021 Financial Results on February 22, 2022
2/8/2022
Cerus Corporation (Nasdaq: CERS) announced today that its fourth quarter and full-year 2021 financial results will be released on Tuesday, February 22, 2022, after the close of the stock market.
-
Cerus Corporation Announces Record Preliminary Fourth Quarter and Full-Year 2021 Product Revenue and Provides Business Update
1/10/2022
Cerus Corporation (Nasdaq: CERS) today announced preliminary product revenue for the fourth quarter and full-year 2021, provided product revenue guidance for 2022 and provided an update on its INTERCEPT Blood System for Cryoprecipitation offering, which is used to produce INTERCEPT Fibrinogen Complex.